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Abstract
 
Apaf-1
 
2/2
 
 or caspase-3
 
2/2
 
 cells treated with a variety of apoptosis inducers manifest apoptosis-
associated alterations including the translocation of apoptosis-inducing factor (AIF) from mito-
chondria to nuclei, large scale DNA fragmentation, and initial chromatin condensation (stage
I). However, when compared with normal control cells, Apaf-1
 
2/2
 
 or caspase-3
 
2/2
 
 cells fail to
exhibit oligonucleosomal chromatin digestion and a more advanced pattern of chromatin con-
densation (stage II). Microinjection of such cells with recombinant AIF only causes peripheral
chromatin condensation (stage I), whereas microinjection with activated caspase-3 or its down-
stream target caspase-activated DNAse (CAD) causes a more pronounced type of chromatin
condensation (stage II). Similarly, when added to purified HeLa nuclei, AIF causes stage I
chromatin condensation and large-scale DNA fragmentation, whereas CAD induces stage II
chromatin condensation and oligonucleosomal DNA degradation. Furthermore, in a cell-free
system, concomitant neutralization of AIF and CAD is required to suppress the nuclear DNA
loss caused by cytoplasmic extracts from apoptotic wild-type cells. In contrast, AIF depletion
alone suffices to suppress the nuclear DNA loss contained in extracts from apoptotic Apaf-1
 
2/2
 
or caspase-3
 
2/2
 
 cells. As a result, at least two redundant parallel pathways may lead to chroma-
tin processing during apoptosis. One of these pathways involves Apaf-1 and caspases, as well as
CAD, and leads to oligonucleosomal DNA fragmentation and advanced chromatin condensa-
tion. The other pathway, which is caspase-independent, involves AIF and leads to large-scale
DNA fragmentation and peripheral chromatin condensation.
Key words: apoptosis-inducing factor • Apaf-1 • chromatin condensation • caspases • caspase-
activated DNase
 
Introduction
 
One of the hallmarks of apoptosis is the degradation and
concomitant compaction of chromatin. It has been gener-
ally assumed that caspases as well as downstream effectors
such as caspase-activated DNase (CAD) and Acinus are rate
limiting for the development of nuclear apoptosis (1–5).
Accordingly, the inactivation of the caspase-3 gene (6, 7)
and that of the caspase activator Apaf-1 (8) can delay cell
death and largely abolish the type of chromatin condensa-
tion observed in normal control cells treated with apoptosis
inducers such as staurosporine (STS) or etoposide. Simi-
larly, the inactivation of CAD prevents advanced chroma-
tin condensation in different cell types (9). However,
caspases and CAD are not the only effectors causing nu-
clear apoptosis. Thus, chromatin condensation has been
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observed in lymphoid cells treated with STS, anti-CD2
(10), anti-CD4, or anti-CXCR4 (11), as well as in fibro-
blasts overexpressing PML (12), even when caspase activa-
tion is inhibited. Partial chromatin condensation is found in
thymocytes undergoing apoptosis in the presence of the
pan-caspase inhibitor Z-VAD.fmk (13). Recently, apopto-
sis-inducing factor (AIF), a mitochondrial intermembrane
flavoprotein, has been found to translocate from mitochon-
dria to nuclei in a caspase-independent fashion. When
added to purified nuclei, recombinant AIF causes caspase-
independent large scale (
 
z
 
50 kb) DNA fragmentation and
a type of peripheral chromatin condensation that resembles
the first stage of nuclear apoptosis (stage I) observed in in-
tact cells undergoing apoptosis (14, 15). Here, we exam-
ined the question of whether several independent pathways
may lead to nuclear apoptosis.
 
Materials and Methods
 
Cells and Microinjection.
 
Mouse embryonic fibroblasts (MEFs)
obtained from caspase 3
 
2/2
 
 (7), Apaf-1
 
2/2
 
 
 
(8), or control mice
were cultured with STS (2 
 
m
 
M), etoposide (100 
 
m
 
M), cisplatin
 
(150 
 
m
 
M), arsenite (50 
 
m
 
M; Sigma-Aldrich), and/or Z-VAD.fmk
(50 
 
m
 
M; Enzyme Systems). Cells were microinjected (pressure
150 hPa; 0.4 s; reference 16) with the following: buffer only; re-
combinant AIF; an inactive deletion mutant of AIF (
 
D
 
1-351; ref-
erence 14); horse cytochrome 
 
c
 
 (Cyt-c; Sigma-Aldrich); recombi-
nant active caspase-3 (17); or inactive inhibitor of CAD (ICAD)/
CAD or active CAD (generated by digestion of the 250 nM
ICAD–CAD complex with 3 U of caspase-3 in 10 
 
m
 
M of CAD
buffer; 30 min at room temperature, followed by addition of 100
 
m
 
M Ac-DEVD.fmk; Enzyme systems). After microinjection,
cells were cultured for 180 min and stained for 10 min with
the mitochondrial transmembrane potential (
 
DC
 
m
 
)-sensitive dye
CMXRos (100 nM) and the DNA-intercalating dye Hoechst
33342 (1.5 
 
m
 
M; reference 16). Microinjected viable cells (100 per
session; two to three independent sessions of injection) were
identified by inclusion of 0.25% (wt/vol) FITC-dextran (green
fluorescence) in the injectate. Only the blue and red fluorescence
was recorded.
 
Immunofluorescence Staining.
 
Fixed and permeabilized MEFs
were stained for AIF and Cyt-c as described (14, 15). A rabbit
polyclonal antiserum, CM1 (revealed as anti-AIF), was used to
detect the p18 subunit of cleaved caspase-3 (18). Unfixed cells
were incubated for 15 min with 1.2 
 
m
 
M 
 
DC
 
m
 
-sensitive JC-1
(Molecular Probes). Confocal microscopy was performed on a
Figure 1. Mitochondrial and nuclear features of apoptosis in
Apaf-12/2 and caspase-32/2 cells. MEFs from control mice (wild-
type), Apaf-12/2, or caspase-32/2 knockout mice were treated for
24 h with 2 mM STS (A and B), 100 mM etoposide, 150 mM cis-
platin, 50 mM arsenite (B) and/or 50 mM Z-VAD.fmk (right
panels only), followed by determination of the fall of the DCm
(measured as a reduction of the red fluorescence emitted by the
DCm-sensitive dye JC-1), mitochondrio-nuclear, and mitochondrio-cytosolic translocation of AIF or Cyt-c respectively (determined by immunostain-
ing), proteolytic activation of caspase-3 (detected with an antibody specific for active caspase-3), or nuclear morphology (detected with Sytox-green). In-
dividual cells demonstrated in A are shown after 8 h (wild-type) or 24 h (Apaf-12/2, caspase-32/2) of treatment with STS and are representative for the
dominant phenotype. The chromatin condensation of wild-type cells cultured with STS was regarded as stage II of nuclear apoptosis, whereas Apaf-12/2
or caspase-32/2 cells manifest a stage I pattern of chromatin condensation. Kinetic analyses of apoptotic parameters induced by STS (n), etoposide (h),
cisplatin (j), arsenite (s) and/or Z-VAD.fmk (right panels) are shown in B. This experiment has been repeated three times, yielding comparable results.
Electron microscopy (C), large scale DNA fragmentation (D), and oligonucleosomal DNA fragmentation (E) of cells treated as in A are also shown. 
574
 
Nuclear Apoptosis Pathways
Leica TC-SP equipped with an ArKr laser mounted on an in-
verted Leica DM IFBE microscope with an 63 
 
3
 
 1.32 numerical
aperture oil objective. Two stages of nuclear apoptosis were dis-
tinguished by staining with 25 nM Sytox-green (Molecular
Probes) for 15 min at room temperature. Stage I was character-
ized by rippled nuclear contours and a rather partial chromatin
condensation, and stage II by a more pronounced pattern of
chromatin condensation (14, 15).
 
Electron Microscopy.
 
Cells were fixed in pellets for 1 h at 4
 
8
 
C
with 1.6% glutaraldehyde in 0.1 M sodium phosphate buffer, pH
7.4, washed three times, and then post-fixed in 1% osmic acid in
phosphate buffer before scrapping, dehydration, and embedding.
Ultrathin sections mounted on 200 mesh grids were examined in
a JEOL 1200 EX electron microscope.
 
DNA Gel Electrophoresis.
 
Oligonucleosomal DNA fragmen-
tation was detected by agarose gel electrophoresis (19). For pulse
Figure 2. Microinjection of apoptosis-
regulatory proteins into Apaf-12/2 and
caspase-32/2 cells. MEFs from control mice
(wild-type), Apaf-12/2, or caspase-32/2
knockout mice were microinjected with the
indicated protein (5 mM AIF, 5mM AIFD1-
351, 25 mM Cyt-c 1U/ml caspase-3, 250
nM ICAD/CAD protein, or 250 nM acti-
vated CAD), followed by staining with
Hoechst 33342 (blue fluorescence) and the
DCm-sensitive dye CMXRos (red fluores-
cence). Representative phenotypes obtained
2 h after injection are shown in A. Mean
values 6 SD of three independent experi-
ments are shown in B. Note that two stages
(I and II) of nuclear chromatin condensation
can be distinguished. Stage I resembles the
nuclear apoptosis of Apaf-1 2/2 cells (Fig. 1,
A and C), whereas stage II corresponds to
that observed in apoptotic wild-type cells
stimulated with STS (Fig. 1, A and C). 
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field gel electrophoresis, DNA was prepared from agarose plugs
(10
 
6
 
 cells; reference 20) and analyzed in a Bio-Rad CHEF-DR II
(1% agarose; TBE; 200 V; 24 h; pulse wave 60 s; 120
 
8
 
 angle; Bio-
Rad Laboratories).
 
Cell-free Systems of Nuclear Apoptosis.
 
Cytosols from MEFs
stimulated for 24 h with STS (2 
 
m
 
M), etoposide (100 
 
m
 
M), or
cisplatin (150 
 
m
 
M) were prepared in cell-free system buffer (50
 
m
 
l/10
 
6
 
 cells) supplemented with 50 
 
m
 
M Z-VAD.fmk, as previ-
ously described (21). Immunodepletion of AIF (or sham immu-
nodepletion) was performed using an anti-AIF antiserum (or pre-
immune serum) and protein A/G coupled to agarose (Santa-Cruz
Biotechnology, Inc.; reference 14). Purified HeLa cell nuclei
were exposed to cytolic extracts (2 
 
m
 
g/
 
m
 
l protein), AIF (14),
CAD, ICAD (4), caspase-3 (17), and/or the AIF inhibitor 
 
para
 
-
chloromercuriphenylsulfonic acid (PCMPS; Sigma-Aldrich;
reference 22) in cell-free system buffer (23), and nuclear DNA
 
content was quantitated by cytofluorometry after staining with
propidium iodide (14).
 
Results and Discussion
 
Mitochondrial Membrane Permeabilization, Initial Nuclear
Apoptosis, and Large Scale DNA Fragmentation Occur in Apaf-
1
 
2/2
 
 and caspase-3
 
2/2
 
 Cells.
 
Apaf-1
 
2/2
 
 or caspase-3
 
2/2
 
cells, as well as control MEF, responded to four different
apoptosis inducers (STS, etoposide, cisplatin or arsenite) by
manifesting a decrease in the 
 
DC
 
m
 
, translocation of AIF
from mitochondria to nuclei, and translocation of Cyt-c
from mitochondria to the cytoplasm (Fig. 1, A and B). As
expected, at no time point did Apaf-1
 
2/2
 
 or caspase-3
 
2/2
 
MEFs stain with an antibody specific for activated caspase-3
Figure 3. Apoptotic nuclear features induced by AIF and CAD in a cell-free system. HeLa nuclei were exposed to 200 nM AIF (120 min), 250 nM ac-
tivated CAD (recombinant CAD/ICAD protein digested with caspase-3 inhibited or not with Ac-DEVD.fmk; 15 or 120 min), followed by staining with
Hoechst 33342 (A) or electron microscopy (B). (C–E) In addition, nuclei were left untreated (1) or incubated for 120 min with: 200 nM AIF (2); AIF
and 30 mM of PCMPS (3); AIF and 500 nM ICAD (4); caspase-3 (5); 250 nM CAD–ICAD (6); 250 nM activated CAD (7); CAD–ICAD treated with
50 mM of Ac-DEVD.fmk before addition of caspase-3 (8); CAD–ICAD treated with 50 mM of Ac-DEVD.fmk after activation of CAD by caspase-3 (9);
active CAD and ICAD (10); and active CAD and PCMPS. This was followed by staining with propidium iodide and flow cytometric determination of
the frequency of hypoploid nuclei (C; X 6 SD of four experiments), determination of large scale DNA fragmentation (D) and assessment of oligonucleo-
somal DNA fragmentation (E). (F) The kinetics of large scale DNA fragmentation induced by CAD (100 nM) was determined at different time points:
nuclei untreated (1); incubated for 5 min (2); incubated for 15 min (3); incubated for 30 min (4); or incubated for 60 min (5). (G) Oligonucleosomal
DNA fragmentation was assessed after exposure of control nuclei (1) to AIF alone (200 nM; 120 min; 2), CAD alone (250 nM; 120 min; 3), or after se-
quential exposure of nuclei, first to AIF, then to CAD (4). 
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(Fig. 1 A). The nuclear phenotype manifested by Apaf-1
 
2/2
 
or caspase-3
 
2/2
 
 cells appeared clearly distinct from that of
control cells. Apaf-12/2 or caspase-32/2 cells (Fig. 1, A–C)
only manifested a minor peripheral chromatin condensa-
tion (stage I), as was also found in control cells after
short-term incubation with STS. However, Apaf-12/2 or
caspase-32/2 cells failed to develop the more advanced
chromatin condensation (stage II) of control cells (Fig. 1,
A–C). None of the mitochondrial parameters nor the pat-
tern or kinetics of chromatin condensation of Apaf-12/2 or
caspase-32/2 cells (Fig. 1, A and B) were influenced by ad-
dition of the pan-caspase inhibitor Z-VAD.fmk. However,
Z-VAD.fmk arrested the nuclear apoptosis of control wild-
type cells at stage I (Fig. 1, A and B). At the ultrastructural
level, nuclei from apoptotic Apaf-12/2 or caspase-32/2 cells
demonstrated a rather partial chromatin condensation, with
patches of chromatin abutting to the apparently intact en-
velope and without nucleolar degradation (Fig. 1 C). As a
biochemical correlation of the morphological features of
caspase-independent apoptosis, Apaf-12/2 or caspase-32/2
cells developed large scale DNA fragmentation to z50 kb
(Fig. 1 D), yet failed to show the (presumably CAD-medi-
ated; references 1, 2, 9) oligonucleosomal DNA fragmenta-
tion (Fig. 1 E).
Figure 4. Inhibition of AIF and CAD re-
veals two parallel pathways of nuclear apop-
tosis. (A) HeLa nuclei were left untreated
(control nuclei) or incubated for 2 h with
cytosolic extracts obtained from untreated
cells (Control) or cytosols (CS) from STS-
treated wild-type MEFs, followed by stain-
ing with propidium iodide and flow cyto-
metric quantitation of DNA content. Extracts
were subjected to immunodepletion of AIF,
sham immunodepletion, and/or addition of
recombinant ICAD protein (500 nM). (B)
Comparison of cytosols obtained from wild-
type, Apaf-12/2, and caspase-32/2 MEFs
stimulated with three different apoptosis in-
ducers (STS, etoposide, and cisplatin). Cyto-
sols were evaluated for their capacity to in-
duce nuclear DNA loss in purified HeLa
nuclei (quantitated as in A) after depletion of
AIF and/or addition of ICAD, as indicated.
Cytosols from untreated control cells in-
duced $10% of nuclear apoptosis. Results
are means of triplicates (X 6 SD) and are
representative of three independent deter-
minations.577 Susin et al. Brief Definitive Report
The Apaf-1/Caspase/CAD Pathway and AIF Account for
Two Different Phenotypes of Nuclear Apoptosis. Wild-type,
Apaf-12/2, or caspase-32/2 cells were microinjected with
Cyt-c, active caspase-3, CAD, or AIF. As expected (8, 24),
Cyt-c alone induced signs of apoptosis (DCm loss, chroma-
tin condensation) in wild-type cells, but not in Apaf-12/2
nor in caspase-32/2 cells (Fig. 2, A and B). In contrast, mi-
croinjection of active caspase-3 provoked full-blown apop-
tosis (stage II) in all three cell types (Fig. 2 B). Similarly,
AIF and CAD induced apoptosis in all cell types (Fig. 2, A
and B). AIF induced a peripheral type of chromatin con-
densation (similar to the caspase-independent stage I, Fig. 1
A), whereas CAD (and its activator caspase-3) provoked a
more advanced pattern of nuclear compaction (similar to
the caspase-dependent stage II, Fig. 1 A). The differential
effect of AIF and CAD was confirmed in a cell-free system.
When added to purified HeLa nuclei, AIF caused periph-
eral chromatin condensation (Fig. 3, A and B), whereas
CAD induced a much stronger type of chromatin compac-
tion accompanied by a reduction in nuclear size (Fig. 3, A
and B). Moreover, AIF alone caused large scale DNA frag-
mentation (Fig. 3 D), yet was unable to provoke the “lad-
der type” oligonucleosomal chromatin digestion (Fig. 3 E).
In contrast, CAD provoked the digestion of DNA in two
steps, first into z50 kb (at low doses; Fig. 3 F) and then
into mono- and oligomers of z200 bp (at high doses; Fig.
3 E). Moreover, CAD could act on AIF-pretreated nuclei
(which lack oligonucleosomal DNA fragmentation, Fig. 3
E) to induce oligonucleosomal fragmentation (Fig. 3 G). In
conclusion, AIF and CAD cause two morphologically and
biochemically distinct types of nuclear apoptosis.
CAD and AIF Act in Parallel Pathways of Nuclear Apop-
tosis. As described above, AIF and CAD induced nuclear
apoptosis independently from each other, both upon mi-
croinjection into intact cells (Fig. 2) and upon addition to
purified nuclei (Fig. 3). ICAD inhibited CAD, yet did not
antagonize AIF (Fig. 3, C–E). Cytosolic extracts from
wild-type MEFs undergoing apoptosis in response to STS,
etoposide, or cisplatin were found to contain a biological
activity which caused nuclear DNA loss in vitro upon addi-
tion to purified HeLa cells. Addition of ICAD failed to
block this activity (Fig. 4, A and B). Similarly, immunode-
pletion of AIF had no major inhibitory effect on such ex-
tracts (Fig. 4, A and B). However, if AIF immunodepletion
was combined with ICAD, apoptotic DNA loss was abol-
ished (Fig. 4, A and B). Cytosolic extracts from Apaf-12/2
Figure 5. Scenario for the different phases of
nuclear Apoptosis. AIF causes large scale chro-
matin fragmentation and a peripheral chromatin
condensation (stage I). CAD causes a more ad-
vanced oligonucleosomal DNA fragmentation
and DNA condensation (stage II).578 Nuclear Apoptosis Pathways
and caspase-32/2 cells treated with different apoptosis in-
ducers also contained an activity which induced nuclear
apoptosis in the cell-free system (Fig. 4 B). In contrast to
wild-type extracts, AIF depletion from Apaf-12/2 and
caspase-32/2 extracts sufficed to inhibit the apoptosis-induc-
ing activity, indicating that AIF is the principal factor re-
sponsible for nuclear apoptosis in such cells.
Concluding Remarks. Apoptosis-associated chromatin con-
densation and degradation may be expected to serve two
purposes, namely to facilitate shrinkage (which in turn facili-
tates heterophagic removal of the apoptotic cells) and to pre-
vent the DNA of the dead cell, which may include viral ge-
nomes or mutated genes including oncogenes, from being
incorporated into adjacent cells. As shown here, at least two
parallel and redundant pathways lead to nuclear apoptosis.
One of these pathways involves caspases, ICAD, and CAD,
and leads to oligonucleosomal DNA fragmentation and ad-
vanced chromatin condensation. The second, caspase-inde-
pendent, pathway involves AIF and leads to large-scale DNA
fragmentation and peripheral chromatin condensation (Figs.
1–3). These pathways may be activated in a sequential fash-
ion, as the AIF-induced phenotype of nuclear apoptosis
(stage I) normally precedes that induced by CAD (stage II;
Figs. 1 and 5) and large scale DNA fragmentation precedes
internucleosomal DNA cleavage in several models of apop-
tosis (15, 25–27). Moreover, both pathways can act in a re-
dundant fashion as suggested by the fact that, in a cell-free
system involving cytoplasmic extract as apoptosis inducer,
nuclear apoptosis is only prevented when both CAD and
AIF are inhibited (Figs. 4 and 5). Recently, the existence of
another chromatin condensation factor, Acinus, which re-
quires activation by caspase-3 and another, unknown, pro-
tease has been reported (5). It may be speculated that Acinus
is not fully activated in the cytosolic extract system used
herein or, alternatively, that Acinus requires activation by
AIF and/or is inhibited by ICAD.
In apparent contrast to the data reported here and in ref-
erence 4, a caspase-resistant mutant of ICAD completely
prevents STS-induced DNA fragmentation in Jurkat cells,
even at the level of large-scale DNA fragmentation (28).
This may imply that the AIF pathway was not activated (or
blocked?) in this cell type. The fact that the contribution of
AIF (or other factors) to nuclear apoptosis varies is also sug-
gested by variations in the observed effect of caspase inhibi-
tors on apoptotic nuclear ultrastructure in different experi-
mental systems, ranging from suppression of most signs of
chromatin condensation (13) to no inhibition at all (10–12).
AIF is expressed in an ubiquitous fashion (14), suggesting
that factors other than AIF expression, e.g., endogenous
AIF inhibitors or the absence of AIF targets, must explain
these differences. Microinjection of an anti-AIF antibody
prevents chromatin condensation induced by atractyloside
or staurosporine (14), whereas depletion of AIF from cyto-
solic extracts (of wild-type cells) does not suffice to prevent
chromatin condensation induced by such extracts (Fig. 4).
This apparent paradox may reflect the fact that AIF is re-
leased from mitochondria before Cyt-c, correlating with
stage I of apoptosis (15). Thus, when choosing a suitable
time frame in short-term microinjection experiments, neu-
tralization of AIF prevents the appearance of stage I of apop-
tosis. Moreover, AIF is a factor that causes the release of
Cyt-c (14). Thus, AIF neutralization may be expected to
retard the release of Cyt-c and the subsequent caspase/CAD
activation that leads to stage II chromatin condensation.
Irrespective of these theoretical considerations, our data
indicate the existence of at least two pathways leading to
chromatin condensation and degradation during apoptosis.
Why the process of apoptotic chromatin condensation is so
complex and whether these pathways are connected at the
molecular level by a common action on sessile nuclear pro-
teins with proapoptotic potential remains an open question
for future investigation.
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